JP2023527794A - トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法 - Google Patents

トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法 Download PDF

Info

Publication number
JP2023527794A
JP2023527794A JP2022572329A JP2022572329A JP2023527794A JP 2023527794 A JP2023527794 A JP 2023527794A JP 2022572329 A JP2022572329 A JP 2022572329A JP 2022572329 A JP2022572329 A JP 2022572329A JP 2023527794 A JP2023527794 A JP 2023527794A
Authority
JP
Japan
Prior art keywords
cancer
tucatinib
subject
trastuzumab
her2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022572329A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023527794A5 (https=
Inventor
ルーク ウォーカー，
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2023527794A publication Critical patent/JP2023527794A/ja
Publication of JP2023527794A5 publication Critical patent/JP2023527794A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022572329A 2020-05-29 2021-05-28 トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法 Pending JP2023527794A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063032223P 2020-05-29 2020-05-29
US63/032,223 2020-05-29
PCT/US2021/034715 WO2021243123A1 (en) 2020-05-29 2021-05-28 Methods of treating her2 positive cancer with tucatinib in combination with trastuzumab and an oxaliplatin-based chemotherapy

Publications (2)

Publication Number Publication Date
JP2023527794A true JP2023527794A (ja) 2023-06-30
JP2023527794A5 JP2023527794A5 (https=) 2024-05-29

Family

ID=76601765

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022572329A Pending JP2023527794A (ja) 2020-05-29 2021-05-28 トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法

Country Status (10)

Country Link
US (1) US20230173067A1 (https=)
EP (1) EP4157257A1 (https=)
JP (1) JP2023527794A (https=)
KR (1) KR20230027068A (https=)
CN (1) CN115768416A (https=)
AU (1) AU2021281336A1 (https=)
CA (1) CA3183592A1 (https=)
IL (1) IL298538A (https=)
MX (1) MX2022014886A (https=)
WO (1) WO2021243123A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120091828A (zh) * 2022-10-12 2025-06-03 中外制药株式会社 含有肽、表面活性剂和聚合物的组合物
WO2024130003A1 (en) * 2022-12-15 2024-06-20 Bolt Biotherapeutics, Inc. Cancer combination treatment method
CN117224689B (zh) * 2023-11-16 2024-02-23 上海复宏汉霖生物技术股份有限公司 联合抗her2抗体和化疗剂治疗胃癌的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526381A (ja) * 2015-09-04 2018-09-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バルリチニブおよび抗癌剤を含んでなる併用療法
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers
JP2020509024A (ja) * 2017-03-02 2020-03-26 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
AU2012323890A1 (en) 2011-10-14 2014-05-29 Array Biopharma Inc. Polymorphs of arry-380, a selective ErbB2 inhibitor and pharmaceutical compositions containing them
WO2013056108A2 (en) 2011-10-14 2013-04-18 Array Biopharma Inc. Solid dispersion
EP3727368A4 (en) * 2017-12-19 2021-10-20 Abraxis BioScience, LLC METHOD OF TREATMENT IN COLON CANCER WITH NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018526381A (ja) * 2015-09-04 2018-09-13 アスラン ファーマシューティカルズ ピーティーイー リミテッド バルリチニブおよび抗癌剤を含んでなる併用療法
JP2020509024A (ja) * 2017-03-02 2020-03-26 ジェネンテック， インコーポレイテッド Ｈｅｒ２陽性乳癌のアジュバント治療
WO2018201016A1 (en) * 2017-04-28 2018-11-01 Cascadian Therapeutics, Inc. Treatment of her2 positive cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNALS OF ONCOLOGY, vol. 28(Supp. 5):576, JPN6025023575, September 2017 (2017-09-01), ISSN: 0005617909 *
BULLETIN DU CANCER, vol. 102:324-331, JPN7025002574, 3 March 2015 (2015-03-03), ISSN: 0005617910 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 382:597-609, JPN6025023574, 11 December 2019 (2019-12-11), ISSN: 0005617908 *

Also Published As

Publication number Publication date
IL298538A (en) 2023-01-01
US20230173067A1 (en) 2023-06-08
AU2021281336A1 (en) 2022-12-15
KR20230027068A (ko) 2023-02-27
WO2021243123A1 (en) 2021-12-02
CA3183592A1 (en) 2021-12-02
CN115768416A (zh) 2023-03-07
MX2022014886A (es) 2023-01-04
EP4157257A1 (en) 2023-04-05

Similar Documents

Publication Publication Date Title
AU2022241509B2 (en) Treatment of HER2 positive cancers
CN114945369A (zh) 图卡替尼与抗her2抗体-药物缀合物联合治疗her2阳性乳腺癌的方法
TW202521120A (zh) 藥物組合物及其應用
KR102439911B1 (ko) 제약학적 복합제제
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
JP2023527794A (ja) トラスツズマブ及びオキサリプラチン系化学療法と組み合わせたツカチニブによるｈｅｒ２陽性癌を治療する方法
KR20240074779A (ko) 약학적 조성물 및 이의 용도
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN116723858A (zh) 图卡替尼联合曲妥珠单抗、紫杉烷和vegfr-2拮抗剂治疗her2阳性癌症的方法
US20200197396A1 (en) Treatment of breast cancer using combination therapies comprising an akt inhibitor, a taxane, and a pd-l1 inhibitor
JP2022553041A (ja) Ｈｅｒ２陽性乳がんをカペシタビンおよびトラスツズマブと併用してツカチニブで治療する方法
KR20250093563A (ko) Egfr 억제제의 말론산염 및 글라이콜산염
TW202300153A (zh) 使用serd組合給藥方案治療癌症之方法
HK40078614A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with an anti-her2 antibody-drug conjugate
WO2023230429A1 (en) Methods of treating colorectal cancer with tucatinib in combination with an anti-her2 antibody
HK40076724A (en) Methods of treating her2 positive breast cancer with tucatinib in combination with capecitabine and trastuzumab
CN119818513A (zh) 治疗儿科患者的癌症的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240521

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240521

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250110

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250116

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250616

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260105